The results of our study provide a new strategy for using PARPi alone or in combination with DNA-damaging agents (radio or chemotherapy) to treat ARID1A-mutated cancers, as well as many other PI3K/Akt1-induced cancers. This evidence concerns the gene PIK3CA and cancer.